Nektar Therapeutics (NASDAQ:NKTR) has tumbled 6.01% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 7.3% in the last four weeks. The stocks have underperformed the S&P 500 by 4.89% during the past week but Nektar Therapeutics (NASDAQ:NKTR) it has outperformed the index in 4 weeks by 6.32%.
Nektar Therapeutics (NASDAQ:NKTR): The stock opened at $15.05 on Friday but the bulls could not build on the opening and the stock topped out at $15.48 for the day. The stock traded down to $14.74 during the day, due to lack of any buying support eventually closed down at $14.85 with a loss of -1.13% for the day. The stock had closed at $15.02 on the previous day. The total traded volume was 1,957,726 shares.
The company shares have rallied 25.53% from its 1 Year high price. On Dec 29, 2015, the shares registered one year high at $17.55 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $14.75 and the 200 Day Moving Average price is recorded at $14.21.
On the companys insider trading activities,The director of Nektar Therapeutics, Chess Robert sold 5,000 shares at $15.5 on June 1, 2016. The Insider selling transaction had a total value worth of $77,500. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Currently the company Insiders own 6.76% of Nektar Therapeutics shares according to the proxy statements.
Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Companys pipeline is comprised of drug candidates for therapeutic areas, including oncology, pain, anti-infectives, and immunology. The Companys research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics, including small molecule oral and parenteral drugs, proteins, peptides and antibody fragments.